International journal of clinical practice | 2021
New Chalcone Derivatives as Effective Anti-SARS-CoV-2 Agents.
Abstract
AIMS\nFlavonoids and related compounds, such as quercetin-based antiviral drug Gene-Eden-VIR/Novirin, inhibit the protease of severe acute respiratory syndrome coronavirus (SARS-CoV-2). The alkylated chalcones isolated from Angelica keiskei inhibit SARS-CoV proteases. In this study, we aimed to compare the anti-SARS CoV-2 activities of both newly synthesized chalcone derivatives and these two drugs.\n\n\nMETHODS\nThe current study aimed to determine the potent antiviral activity of newly synthesized chalcone derivatives against SARS-CoV-2 by calculating the RT-PCR cycling threshold (Ct) values.\n\n\nRESULTS\nAntiviral activities of the compounds varied due to being dose dependent. Compound 6, 7, 9 and 16 were highly effective against SARS-CoV-2 at concentrations of 1.60 µg/mL. Structure-based virtual screening was carried out against the most important druggable SARS-CoV-2 targets, viral RNA-dependent RNA polymerase (RdRp), to identify putative inhibitors that could facilitate the development of potential anti-COVID-19 drug candidates.\n\n\nCONCLUSIONS\nComputational analyses identified eight compounds inhibiting each target, with binding affinity scores ranging from -4,370 to -2,748 kcal/mol along with their toxicological, ADME, and drug-like properties.